Compare BioNano Genomics Inc (BNGO) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs PulteGroup, Inc. — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while PulteGroup, Inc. trades at $129.42 (market cap $25.22B). The key difference: PulteGroup, Inc. is far larger — about 1846.3× BioNano Genomics Inc's market cap, and PulteGroup, Inc. pays a 0.79% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PHM | |
|---|---|---|
Market Cap | $13.66M | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $142.56 |
52-Week Low | $1.06 | $110.11 |
Enterprise Value | $16.26M | $25.64B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
PulteGroup (PHM) trades at $130.05, down 2.14% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows mixed earnings performance, beating Q2 2026 estimates but missing in Q4 2025 and Q1 2026. Recent news highlights operational expansion into Northwest Florida and corporate recognition as a Great Place to Work, while financials indicate solid profitability with an 11.62% net margin and a P/E of 13.53.
Outlook remains cautiously optimistic with a consensus price target of $137.20, suggesting modest upside. Risks include margin pressure from housing market affordability challenges and volatile cash flows. Institutional sentiment leans neutral with 50% hold ratings, reflecting balanced Wall Street views amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
